Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A dose-escalation and safety gene therapy study in a model of CMT4C neuropathy.

Gene therapy·2026
Same author

The p.(Leu97Ile) variant expands the genetic landscape of NEFL-associated Charcot-Marie-tooth neuropathies.

Human molecular genetics·2026
Same author

Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis.

Acta neuropathologica·2026
Same author

Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans.

Cell reports. Medicine·2026
Same author

A muscular dystrophy associated with bi-allelic LEMD2 variants: Expanding the genotype of nuclear envelopathies.

Brain pathology (Zurich, Switzerland)·2026
Same author

Mitochondrial energetic failure underlies FLVCR1-related sensory neuropathy.

Communications biology·2026

Related Experiment Video

Updated: Mar 17, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.9K

Optimization of Internally Deleted Dystrophin Constructs.

Mojgan Reza1, Steve H Laval1, Andreas Roos1,2

  • 11 John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, University of Newcastle , Newcastle upon Tyne, United Kingdom .

Human Gene Therapy Methods
|August 2, 2016
PubMed
Summary

Researchers developed four human minidystrophins for Duchenne muscular dystrophy (DMD) gene therapy. These constructs, including two novel ones with nNOS-anchoring domains, were tested in mdx mice to assess their therapeutic potential.

Keywords:
assay developmentdisease modelsmusclevector productionvectors

More Related Videos

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.3K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

Related Experiment Videos

Last Updated: Mar 17, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.9K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.3K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by dystrophin deficiency.
  • Current gene replacement therapies for DMD aim to restore dystrophin protein function.
  • Previous studies partially characterized modified dystrophin protein products, highlighting the need for further optimization.

Purpose of the Study:

  • To design and produce human minidystrophin constructs for lentiviral vector-mediated gene therapy.
  • To evaluate the in vivo functionality of novel minidystrophins, including those retaining the nNOS-anchoring domain.
  • To assess the suitability of these constructs for ex vivo gene delivery to stem cells.

Main Methods:

  • Designed and produced four human minidystrophin constructs within lentiviral vectors.
  • Investigated the functionality of minidystrophins in adult dystrophin-deficient mdx mice.
  • Conducted immunohistochemical and morphometric analyses to evaluate protein expression and muscle integrity.

Main Results:

  • Four human minidystrophins were successfully produced using lentiviral vectors.
  • Two novel minidystrophins retained the nNOS-anchoring domain, potentially restoring sarcolemmal nNOS.
  • Initial functional assessments in mdx mice provided data on construct suitability for further preclinical studies.

Conclusions:

  • Developed minidystrophin constructs show promise for DMD gene therapy.
  • The inclusion of the nNOS-anchoring domain may be crucial for restoring full dystrophin function.
  • These findings support the advancement of optimized minidystrophins for ex vivo stem cell-based gene therapy in DMD.